Drug Trial Radar · NCT07044336
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Oct 15, 2027
Study completion Jul 17, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
Conditions
- Endometrial Cancer
- Malignant Solid Tumour
Interventions
Puxitatug SamrotecanDrug
2.4 mg/kg on Day 1 Q3W Route of administration: IV infusion
DoxorubicinDrug
60 mg/m2 on Day 1 Q3W Route of administration: IV
PaclitaxelDrug
80 mg/m2 on Days 1, 8, and 15 in 28-day cycle Route of Administration: IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) for Arm A vs Arm BTime frame: Approximately 3 years
- Overall survival (OS) for Arm A vs Arm BTime frame: Approximately 3 years
Locations
320 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona · Not yet recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Los Angeles, California · Withdrawn
Research Site
Orange, California · Recruiting
Research Site
Washington D.C., District of Columbia · Not yet recruiting
Research Site
Jupiter, Florida · Recruiting
Research Site
Miami, Florida · Not yet recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Miami Beach, Florida · Recruiting
Research Site
New Port Richey, Florida · Recruiting
Research Site
Orlando, Florida · Recruiting
Research Site
Tampa, Florida · Not yet recruiting
Research Site
West Palm Beach, Florida · Recruiting
Research Site
Honolulu, Hawaii · Not yet recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Peoria, Illinois · Recruiting
Research Site
Urbana, Illinois · Recruiting
Research Site
Fort Wayne, Indiana · Recruiting
Research Site
Indianapolis, Indiana · Recruiting
Research Site
Scarborough, Maine · Recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Baltimore, Maryland · Recruiting
Research Site
Silver Spring, Maryland · Recruiting
Research Site
Ann Arbor, Michigan · Not yet recruiting
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
Detroit, Michigan · Withdrawn
Research Site
Minneapolis, Minnesota · Recruiting
Research Site
Camden, New Jersey · Not yet recruiting
Research Site
Paramus, New Jersey · Recruiting
Research Site
Albuquerque, New Mexico · Recruiting
Research Site
Brooklyn, New York · Not yet recruiting
Research Site
Stony Brook, New York · Recruiting
Research Site
The Bronx, New York · Recruiting
Research Site
White Plains, New York · Recruiting
Research Site
Greenville, North Carolina · Recruiting
Research Site
Pinehurst, North Carolina · Recruiting
Research Site
Cincinnati, Ohio · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Columbus, Ohio · Recruiting
Showing 40 of 320 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.